Silo Pharma Secures U.S. Patent for PTSD Treatment SPC-15
Event summary
- Silo Pharma received a U.S. patent allowance for SPC-15, its intranasal PTSD treatment, on September 18, 2026.
- The patent covers compositions and methods for preventing or mitigating stress-induced behavioral responses.
- A corresponding patent for SPC-15 was previously issued by the Japan Patent Office earlier in 2026.
- Silo Pharma's CEO Eric Weisblum highlighted the strategic importance of this patent for advancing SPC-15's development.
The big picture
Silo Pharma's U.S. patent for SPC-15 reinforces its intellectual property strategy, a critical move as it competes in the underserved PTSD treatment space. The company's focus on stress-induced psychiatric disorders aligns with broader industry trends toward targeted CNS therapies, though its developmental-stage status presents execution risks. The patent also underscores Silo's dual strategy of advancing biopharmaceuticals alongside its AI subsidiary, QwikAgents.
What we're watching
- Development Timeline
- The pace at which Silo Pharma advances SPC-15 through clinical trials following this patent allowance.
- Market Positioning
- How this patent strengthens Silo Pharma's competitive edge in the PTSD treatment market.
- IP Strategy
- Whether Silo Pharma will leverage this patent to attract partnerships or licensing deals.
Related topics